Sign up
Pharma Capital

Summit Therapeutics shows off potential of Discuva platform at Berlin conference

The presentations are being made at Novel Antimicrobials and AMR Diagnostics 2019, which is being held in Berlin today and tomorrow
bacteria
Many infectious diseases are becoming resistant to current antibiotic treatments

Summit Therapeutics PLC (LON:SUMM) has unveiled two new presentations at an industry conference in Berlin.

The presentations show off the potential of Summit’s Discuva platform, which it is using to identify and develop new antibiotics that infections such as gonorrhoea and staph aren’t resistant to.

READ: Summit’s gonorrhoea antibiotic showing promise

Several programmes of new mechanism antibiotics have emerged from the Discuva Platform, including one targeting gonorrhoea and another targeting ESKAPE pathogens.

Both of those programmes are being discussed at the conference.

“Antimicrobial resistance is a worldwide problem. We need to see scientific innovation to prevent an era of untreatable infections,” said Summit’s president of R&D, David Roblin.

“Through the Discuva Platform, we are using novel science to create targeted, new mechanism antibiotics that are optimised against resistance development.

“Our goal is to develop the most appropriate drug for a specific patient, thereby improving patient outcomes and giving physicians options to address the spread of AMR.”

Summit shares were up 1.6% to 30.5p in early afternoon trading on Thursday.

View full SUMM profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.